Acquisition Completed

Esperion Therapeutics acquisition of Corstasis Therapeutics

US$75m consideration

Announced 3 Mar 2026

Advisers

Corstasis Therapeutics

Target

Financial adviser
Legal adviser

Esperion Therapeutics

Acquirer

Financial adviser
Legal adviser
Target
Corstasis Therapeutics
Acquirer
Esperion Therapeutics
Target based in
United States
Buyer based in
United States
Completed
2 Apr 2026
Sector
Pharma
Tags
Pharma, Cardiovascular

In the league tables

Similar deals

All pharma deals →

Sources

Suggest a correction

A missing adviser, a wrong role or a different outcome. A link to a public source helps.